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Sir,
Subsequent to the European accord on inhaled medication
and inhalation devices in CF [1], and the recent letter outlining
key areas for future research [2], we write to emphasise the
fundamental importance of simultaneously improving adher-
ence to this type of therapy. This is exceptionally low [3,4] and
as such, particularly worrying, with established reliance on
nebulisation for the treatment ofPseudomonas aeruginosa (Psa)
and Burkhoderia cepacia complex (Bcc), and the delivery of
hypertonic saline and mucolytics (e.g., dornase alpha). Prolif-
eration of new aerosolised antibiotics (e.g., Aztreonam Lysine),
and other pharmacological agents currently in development or
clinical trials (e.g., Denufusol and Mannitol), will further
heighten the demands of adhering to this type of treatment.
Although reducing nebulisation times and developing dry
powder preparations may lead to some amelioration, inhalation
therapy in CF rarely offers any immediate clinical effect, is
cumulatively time-consuming and makes CF ‘visible’, three
factors generically known to be associated with poorer
adherence. As drugs do not work in people who do not take
them, we believe there is a looming potential for diminished
clinical effectiveness from this type of treatment and as such,
adherence needs to be addressed with the utmost priority.
Several psychotherapeutic approaches to adherence problems
in CF have proved effective [5], but are time-consuming and
require expertise. However, some psychological techniques (e.g.,
problem-solving and solution focused therapies), and tool-kits,
which can be incorporated into routine practice by CF team
members, show much promise and are currently under investi-
gation. Yet, one of the most important is potentially one of the
simplest; establishing effective communication and interaction
between patients, their families and health carers. This has been
shown to lead to increased satisfaction and improved health
outcomes over traditional expert-led consultations [6]. Failure to
do so leads to missing important opportunities to discuss
adherence problems openly, which in turn, can cause over-
treatment, the cessation ofmedications perceived to be ineffective
and failure to understand the impact of CF treatment on patients'
quality of life [7,8].
Motivational interviewing (MI) is a framework designed to
promote health behaviour change based on four main tenets,
(i) establishing conversations and expressing empathy with1569-1993/$ - see front matter © 2010 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2010.08.012patients, (ii) developing discrepancies between their thoughts,
beliefs and behaviours, (iii) working with resistance to change
rather than confronting it and, (iv) supporting the efforts of
individuals who attempt to change. The process offers key
communicative techniques to utilise during consultations with
patients, particularly adolescents and young adults, who exhibit
poor adherence. Large studies ofMI in a variety of physical health
groups support the efficacy of the approach in tackling sub-
optimal adherence [9]. Whilst to date there are no published
studies aimed specifically at improving adherence to inhalation
therapy, we believe there is no reason why principles with
established efficacy need to be verified again in CF populations
and that enough is known to focus on incorporating the techniques
into routine care and evaluating the effectiveness.
We previously reported on a three-month feasibility study
of telephone-basedMI intervention [10]. This randomly allocated
adults with CF to receive MI treatment (MI Group), or telephone-
contact which was aimed at simply reviewing progress (Non-
Treatment Group). An Adaptive Aerosol Delivery (AAD®)
nebuliser with electronic data recording capabilities (Philips
Respironics Ltd), was used to record adherence. The short
duration of the intervention and small sample size resulted in no
statistically significant differences in adherence behaviour
however, the MI Group scored higher than the Non-Treatment
Group on seven of the nine domains of a CF quality of life
measure (CFQ), at the end of the study, including three domains
in which they had scored below the Non-Treatment Group at
baseline. We attributed this to MI having potentially positive
effects on perceptions held by participants about CF. More
conclusive, was that patients found telephone-based MI to be
acceptable, it being efficient and easy to implement in routine
practice. This underscores the feasibility of establishing the
approaches in routine CF clinic consultations and follow-ups as
opposed to MI being a discrete psychological intervention.
Although MI is becoming increasingly familiar to many
health professionals, the evidence is that without training, they
do not routinely utilise it [11]. We believe that if the full clinical
benefits of nebulised therapies are to be realised in CF patients
both now and in the future, open discussions about adherence
need to take place routinely during out-patient consultations.
Our focus is now on training CF teams in the principles and
practice of MI with the aim of health carers giving consistent
messages to patients who are struggling with adherence, whilst
at the same time, coordinating the approach and supporting
each other in utilising the techniques. Seven teams are cur-
rently participating in the training programme which is due ford by Elsevier B.V. All rights reserved.
456 Letter to the Editorcompletion in December 2010. It comprises of two 4-hour
workshops spaced six months apart. The first of these focuses
on the foundations of MI and establishing the basic principles
of using MI with patients and families in clinical settings. The
second focuses on consolidating the skills and then condensing
them into brief, consultation-based sessions. Early evaluation
of the learning outcomes is encouraging with evidence of the
techniques being valued by CF teammembers and incorporated
into practice. Full evaluation utilises a triumvirate of measures
(self-report, survey and semi-structured telephone-based inter-
view), and will be disseminated in 2011.
Yours sincerely,
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